Investor Alert: Lexaria Bioscience - The Modern Way to Improve Oral Drugs
Lexaria Bioscience began developing DehydraTECH in 2014. Since then, they have strengthened and broadened the technology to an unprecedented degree. T …
Demonstrated Early-Stage Effectiveness
Lexaria Bioscience began developing DehydraTECH in 2014. Since then, they have strengthened and broadened the technology to an unprecedented degree. They are a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs.
DehydraTECH
DehydraTECH is one of the world's newest technologies designed to improve the efficacy of orally administered bioactive molecules. That includes; anti-viral drugs, nicotine, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, and other molecules.
Additionally, DehydraTECH increases bio-absorption by up to 5x, reduces the time of onset from up to 1 – 2 hours to just minutes, masks unwanted tastes, and can reduce unwanted side effects by enabling lower overall dosing.
For more information on Lexaria Bioscience (NASDAQ: LEXX) please click the request investor info button.
Latest Articles
Hot Companies
You might also like
Volta Metals: Powering the Future with Ontario’s Critical Minerals
As global demand for critical minerals surges, Volta Metals is strategically positioned in Northwestern Ontario, exploring lithium and rare metals in proximity to infrastructure and clean energy sources.
.png)
.png)
